119 related articles for article (PubMed ID: 34933726)
21. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
22. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
[TBL] [Abstract][Full Text] [Related]
23. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
Chung HW; Jang S; Lim JB
Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
[TBL] [Abstract][Full Text] [Related]
25. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
26. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
[No Abstract] [Full Text] [Related]
27. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma.
Nissen NI; Kehlet S; Johansen AZ; Chen IM; Karsdal M; Johansen JS; Diab HMH; Jørgensen LN; Sun S; Manon-Jensen T; He Y; Langholm L; Willumsen N
Int J Cancer; 2021 Jul; 149(1):228-238. PubMed ID: 33687786
[TBL] [Abstract][Full Text] [Related]
28. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
29. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma.
Ahmed A; Köhler S; Klotz R; Giese N; Lasitschka F; Hackert T; Springfeld C; Zörnig I; Jäger D; Halama N
Oncoimmunology; 2021; 10(1):1962135. PubMed ID: 34408923
[TBL] [Abstract][Full Text] [Related]
31. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
32. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
33. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.
Kieler M; Unseld M; Wojta J; Kaider A; Bianconi D; Demyanets S; Prager GW
Med Oncol; 2018 Nov; 36(1):1. PubMed ID: 30426271
[TBL] [Abstract][Full Text] [Related]
34. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
37. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
Kimura H; Yamamoto H; Harada T; Fumoto K; Osugi Y; Sada R; Maehara N; Hikita H; Mori S; Eguchi H; Ikawa M; Takehara T; Kikuchi A
Clin Cancer Res; 2019 Mar; 25(6):1936-1947. PubMed ID: 30610103
[TBL] [Abstract][Full Text] [Related]
38. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern.
Kim HW; Lee JC; Paik KH; Kang J; Kim J; Hwang JH
Medicine (Baltimore); 2017 Feb; 96(5):e5926. PubMed ID: 28151872
[TBL] [Abstract][Full Text] [Related]
39. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
Zhang K; Dong S; Jing YH; Gao HF; Chen LY; Hua YQ; Chen H; Chen Z
BMC Cancer; 2020 Jun; 20(1):541. PubMed ID: 32517802
[TBL] [Abstract][Full Text] [Related]
40. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
